Corporate communications in the pharmaceutical industry is unusually high-stakes. Product launches, clinical trial results, regulatory approvals or rejections, pricing controversies, safety issues, and executive leadership changes all generate media and stakeholder attention that can affect share price, employee morale, and the company’s relationships with regulators and payers. For pharma CEOs, communications is a function where personal involvement is sometimes essential but where over-involvement creates bottlenecks and undermines the team’s ability to operate at speed.
This guide explores how pharma CEOs can build a delegation framework for corporate communications and media relations that keeps the CEO at the center of the narrative without making the CEO a bottleneck in the communications operation.
The Communications Functions That Pharma CEOs Must Understand
Before building a delegation framework, it helps to map the distinct functions that typically sit within corporate communications:
Media relations covers relationships with journalists, reporters, and media outlets covering the company, its products, and the broader pharmaceutical industry.
Financial communications covers investor-facing communications, including earnings calls, investor day presentations, and communications related to material events such as acquisitions, partnerships, and pipeline milestones.
Internal communications covers employee-facing messaging, including communications from the CEO to the workforce on strategy, culture, and organizational changes.
Disease awareness and patient communications covers external campaigns that educate patients, caregivers, and the public about disease states and treatment options.
Crisis communications covers rapid response to adverse events, including product safety issues, litigation, regulatory actions, and reputational challenges.
Executive and CEO communications covers the CEO’s personal public profile, including speaking engagements, media interviews, op-eds, LinkedIn presence, and conference appearances.
Each of these functions requires different skills, different governance, and a different delegation approach.
What the CEO Should Retain
The CEO cannot fully delegate communications because the CEO is simultaneously the primary subject of communications, the final approver of the company’s external narrative, and the most credible spokesperson for major announcements.
However, the CEO’s role in communications should be focused on a small number of high-leverage activities:
Owning the company narrative. The CEO is the ultimate author of how the company describes its purpose, strategy, and value to patients and investors. This narrative should be developed in close collaboration with the communications team but reflects the CEO’s authentic voice and strategic perspective. No communications director can develop this narrative independently.
Approving major communications. For material announcements, the CEO should be the final approver of external messaging, particularly for communications that will move markets, affect patient communities, or shape regulatory relationships.
Serving as primary spokesperson for major events. Earnings calls, investor days, product launches, and significant external events typically require CEO presence. These are high-value, high-visibility moments where the CEO’s role is irreplaceable.
Setting the tone for crisis response. When a significant crisis occurs, the CEO needs to be visible and engaged in shaping the response strategy. This does not mean the CEO drafts every press release, but it does mean the CEO’s judgment about how to respond to major events is central to the communications approach.
What the CEO Should Delegate
Everything outside these high-leverage activities should be delegated to a senior communications leader. The day-to-day management of media relationships, the drafting and review of press releases and Q&As, the internal communications calendar, social media management, and the planning of communications events are all operational activities that the communications team should own.
A strong Chief Communications Officer or VP of Corporate Communications should be able to manage these functions without CEO involvement in specific decisions. The CEO’s relationship with the communications leader should be characterized by strategic alignment and regular dialogue, not approval of individual communications outputs.
Building the Right Communications Leadership
Delegation of corporate communications depends entirely on having the right communications leader. For a publicly traded pharma company, the communications leader needs to combine several capabilities: deep experience in pharmaceutical communications, including understanding of disclosure requirements and the science-communications interface; media relationship credibility, meaning the ability to manage relationships with key journalists and publications directly; crisis communications experience, including the composure and judgment to manage rapid-response situations; and executive communications skills, including the ability to develop and maintain the CEO’s public voice.
Not all of these skills are found in a single person. Some pharma companies address this by having a VP of Corporate Communications with a specialized IR leader, a crisis communications agency relationship, and a dedicated executive communications specialist or ghostwriter for the CEO.
The CEO should invest in assessing whether the current communications leadership team has the combined capabilities to manage the function with appropriate independence, and address gaps through hiring, development, or external partnerships.
Structuring the CEO-Communications Director Relationship
The CEO-communications director relationship is one of the most important delegation partnerships in the pharma executive team. When it works well, the communications director understands the CEO’s voice, values, and strategic priorities so well that they can represent those interests effectively without requiring constant CEO input. When it breaks down, the CEO is either reviewing and revising every communications output or is disengaged from a function that is operating without strategic alignment.
The practical structures that support an effective CEO-communications partnership include:
A regular weekly or bi-weekly alignment meeting (30 minutes) where the CEO and communications director review the communications calendar for the coming period, align on key messages for upcoming announcements, and discuss any issues or opportunities in the media landscape.
A shared messaging platform that documents the current state of the company’s core narrative, key messages for each major product and pipeline program, and approved responses to frequently asked questions. This document allows the communications team to operate without CEO approval for routine inquiries while ensuring consistency with the CEO’s strategic direction.
A clear escalation protocol that specifies when the CEO needs to be consulted before a communications decision is made and when the team is empowered to act independently. This protocol should cover media requests, reactive statements, and proactive announcements.
Managing the Interface Between Communications and Other Functions
Corporate communications in pharma does not operate in isolation. It interfaces with investor relations, regulatory affairs, medical affairs, legal, and government relations on a regular basis. One of the CEO’s important delegation contributions is ensuring that these interfaces are well-managed and that the communications function has appropriate authority to coordinate across them.
A common failure mode is communications being treated as a service function by other departments: legal holds up press releases indefinitely for review, IR and communications operate on separate tracks for investor messaging, and medical affairs publishes scientific communications without alignment with the corporate narrative. The CEO should establish clear norms about how communications coordinates with other functions and should back the communications leader when cross-functional disputes arise about message alignment or timing.
The Digital and Social Media Dimension
Social media, digital content, and executive thought leadership have become important components of pharma corporate communications. The CEO’s own social media presence, particularly on LinkedIn, is a communications asset that requires active management but cannot be micromanaged.
The most effective approach is to work with the communications team to develop a CEO social media strategy that defines the topics, tone, and frequency of CEO social content, and then to delegate the drafting of content to the communications team while ensuring the CEO reviews and authentically approves everything posted under their name.
The CEO should not be posting social media content without communications team review, but neither should the communications team be publishing content that the CEO has not genuinely endorsed. The goal is a collaborative content development process that produces authentic CEO content at a sustainable cadence.
Crisis Communications Delegation
Crisis communications is the area where delegation is both most important and most difficult. When a crisis hits, there is natural pressure for the CEO to take direct personal control of all external messaging. This instinct is understandable but often counterproductive. The communications team, working with legal, regulatory, and other relevant functions, is usually better positioned to manage the operational aspects of crisis response: drafting statements, monitoring media coverage, coordinating spokesperson logistics, and managing inbound media inquiries.
The CEO’s crisis communications role should focus on: approving the company’s response strategy and key messages, making the judgment call about whether and when to make public statements personally, and being briefed regularly on the evolution of the crisis and the effectiveness of the response.
The communications director should be empowered to manage the operational crisis response without needing CEO approval for every communication, within the bounds of the agreed strategy. This requires advance investment in crisis communications planning, including scenario rehearsal and pre-approved messaging frameworks for likely crisis scenarios.
For pharma CEOs building broader organizational delegation systems, the regulatory affairs delegation guide provides complementary guidance on managing regulatory communications. For the supply chain communications dimension, the supply chain guide covers relevant territory.
Practical Steps to Improve Communications Delegation
Pharma CEOs who want to improve communications delegation can take several concrete steps:
Assess whether the current communications leadership has the capability to operate with greater autonomy, and invest in any gaps through hiring or development.
Develop a shared messaging platform that documents the company’s current narrative and key messages, giving the team the foundation to operate independently.
Establish a regular CEO-communications director alignment meeting and use it consistently to maintain strategic alignment without ad hoc interruptions.
Define and communicate the escalation framework so that the communications team knows when they need CEO input and when they are empowered to act.
Invest in crisis communications preparedness so that the team is ready to manage crisis situations without the CEO becoming the operational center of gravity.
Review and align on the CEO’s personal communications profile, including speaking engagements, media availability, and social media strategy, so that the communications team can manage the CEO’s calendar and content pipeline proactively.
Conclusion
Corporate communications is a function where the pharma CEO’s direct involvement is both necessary and valuable, but where the scope of that involvement should be carefully bounded. By building a strong communications leadership team, establishing clear governance structures, and defining the escalation framework, pharma CEOs can maintain the authentic personal voice and strategic oversight that effective external communications requires while delegating the operational management of the function to professionals who can execute it with excellence and speed.
Related Reading
For further context, explore Delegation Guide for Affordable Housing Nonprofit CEOs and Delegation Guide for Automotive CEO: Brand Management.